Last reviewed · How we verify
Topical steroid
Topical steroids reduce inflammation and suppress immune responses in the skin by binding to glucocorticoid receptors in dermal and epidermal cells.
Topical steroids reduce inflammation and suppress immune responses in the skin by binding to glucocorticoid receptors in dermal and epidermal cells. Used for Inflammatory and pruritic dermatoses (e.g., eczema, psoriasis, dermatitis), Allergic contact dermatitis, Lichen planus.
At a glance
| Generic name | Topical steroid |
|---|---|
| Also known as | clobetasol propionate |
| Sponsor | University of South Alabama |
| Drug class | Topical corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Topical steroids are corticosteroids applied directly to the skin that penetrate the epidermis and dermis to exert anti-inflammatory, immunosuppressive, and vasoconstrictive effects. They inhibit the production of inflammatory mediators and reduce T-cell infiltration, thereby alleviating itching, redness, and swelling associated with inflammatory skin conditions. The potency varies by formulation and vehicle used.
Approved indications
- Inflammatory and pruritic dermatoses (e.g., eczema, psoriasis, dermatitis)
- Allergic contact dermatitis
- Lichen planus
- Seborrheic dermatitis
Common side effects
- Skin atrophy
- Striae
- Telangiectasia
- Local irritation or burning
- Folliculitis
- Systemic absorption (with prolonged use on large areas)
Key clinical trials
- Loteprednol Etabonate Versus Prednisolone Acetate for Anterior Chamber Granulomas (PHASE4)
- Comparison of a New Masterful Preparation to Kligman's Trio in the Treatment of Melasma (PHASE2)
- Bladder Directed vs. Pelvic Floor Therapy in IC/BPS (PHASE2)
- Treatment of Bullous Pemphigoid With Avdoralimab (IPH5401), an Anti-C5aR1 Monoclonal Antibody (PHASE2)
- Dextenza Versus Topical Steroid Eye Drops for Postoperative Management Following Corneal Crosslinking (PHASE1, PHASE2)
- Clinical Trial to Demonstrate That the Dual Laser Therapy is Effective for the Treatment of Vulvar Lichen Sclerosus (NA)
- Steroid Treatment for Elimination of Rebound Obstruction From Intranasal Decongestants (PHASE2)
- Directed Topical Drug Delivery for Treatment for PASC Hyposmia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |